SAN DIEGO , May 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences:
SAN DIEGO , May 18, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc.  (Nasdaq: NBIX) today announced the presentation of new data from a clinician survey highlighting the functional impact...
SAN DIEGO , May 18, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. Â (Nasdaq: NBIX) today announced the completion of its acquisition of Soleno Therapeutics, Inc., strengthening the company's...
SAN DIEGO , May 6, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of the first peer-reviewed expert recommendations to guide glucocorticoid dose...
Total First-Quarter 2026 Net Product Sales of $811.0 Million, An Increase of 44% Year-Over-Year
SAN DIEGO , May 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that its executives will participate at the Bank of America Health Care Conference 2026 at 11:20...
Barchart Research What to Expect from NBIX Earnings NBIX Generated May 4, 2026 Current Price $134.07 EPS Estimate $$1.28 Consensus Rating Strong Buy Average Move 6.93% Can Neurocrine Biosciences Justify...
SAN DIEGO , May 4, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the release of findings from a new survey revealing the significant impact of tardive...
SAN DIEGO , May 4, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability...